Click for best price
Postpemic Era Drugs for NonSmall Cell Lung Cancer Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Drugs for Non-Small Cell Lung Cancer Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Drugs for Non-Small Cell Lung Cancer industry at home and abroad, estimate the overall market scale of the Drugs for Non-Small Cell Lung Cancer industry and the market share of major countries, Drugs for Non-Small Cell Lung Cancer industry, and study and judge the downstream market demand of Drugs for Non-Small Cell Lung Cancer through systematic research, Analyze the competition pattern of Drugs for Non-Small Cell Lung Cancer, so as to help solve the pain points of various stakeholders in Drugs for Non-Small Cell Lung Cancer industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Drugs for Non-Small Cell Lung Cancer Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Drugs for Non-Small Cell Lung Cancer Market?
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Major Type of Drugs for Non-Small Cell Lung Cancer Covered in Research report:
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Application Segments Covered in Research Market
Hospitals
Clinics
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Drugs for Non-Small Cell Lung Cancer Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
125 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Drugs for Non-Small Cell Lung Cancer Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Drugs for Non-Small Cell Lung Cancer Market by Value
2.2.1 Global Drugs for Non-Small Cell Lung Cancer Revenue by Type
2.2.2 Global Drugs for Non-Small Cell Lung Cancer Market by Value (%)
2.3 Global Drugs for Non-Small Cell Lung Cancer Market by Production
2.3.1 Global Drugs for Non-Small Cell Lung Cancer Production by Type
2.3.2 Global Drugs for Non-Small Cell Lung Cancer Market by Production (%)
3. The Major Driver of Drugs for Non-Small Cell Lung Cancer Industry
3.1 Historical & Forecast Global Drugs for Non-Small Cell Lung Cancer Demand
3.2 Largest Application for Drugs for Non-Small Cell Lung Cancer (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Drugs for Non-Small Cell Lung Cancer Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Drugs for Non-Small Cell Lung Cancer Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Drugs for Non-Small Cell Lung Cancer Average Price Trend
12.1 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in US (2018-2022)
12.2 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Europe (2018-2022)
12.3 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in China (2018-2022)
12.4 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Japan (2018-2022)
12.5 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in India (2018-2022)
12.6 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Korea (2018-2022)
12.7 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Drugs for Non-Small Cell Lung Cancer Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Drugs for Non-Small Cell Lung Cancer
14. Drugs for Non-Small Cell Lung Cancer Competitive Landscape
14.1 Bristol-Myers Squibb
14.1.1 Bristol-Myers Squibb Company Profiles
14.1.2 Bristol-Myers Squibb Product Introduction
14.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 GlaxoSmithKline
14.2.1 GlaxoSmithKline Company Profiles
14.2.2 GlaxoSmithKline Product Introduction
14.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Menarini
14.3.1 Menarini Company Profiles
14.3.2 Menarini Product Introduction
14.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Sanofi
14.4.1 Sanofi Company Profiles
14.4.2 Sanofi Product Introduction
14.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Ziopharm Oncology
14.5.1 Ziopharm Oncology Company Profiles
14.5.2 Ziopharm Oncology Product Introduction
14.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Alchemia
14.6.1 Alchemia Company Profiles
14.6.2 Alchemia Product Introduction
14.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Amgen
14.7.1 Amgen Company Profiles
14.7.2 Amgen Product Introduction
14.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Apotex
14.8.1 Apotex Company Profiles
14.8.2 Apotex Product Introduction
14.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 BioMarin Pharmaceutical
14.9.1 BioMarin Pharmaceutical Company Profiles
14.9.2 BioMarin Pharmaceutical Product Introduction
14.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 CellAct Pharma
14.10.1 CellAct Pharma Company Profiles
14.10.2 CellAct Pharma Product Introduction
14.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Cerulean Pharma
14.12 Cipla
14.13 Cornerstone Pharmaceuticals
14.14 Curis
14.15 CytRx
14.16 Eli Lilly
14.17 Exelixis
14.18 Fresenius Kabi
14.19 Genentech
14.20 Hikma Pharmaceuticals
14.21 Hospira
14.22 Intas Pharmaceuticals
14.23 Karyopharm Therapeutics
14.24 Kyowa Hakko Kirin
14.25 Ligand Pharmaceuticals
15. Conclusion
16. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Demand by Application of Drugs for Non-Small Cell Lung Cancer Industry (Volume)
Figure 2. Drugs for Non-Small Cell Lung Cancer Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2022
Figure 5. US Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Drugs for Non-Small Cell Lung Cancer Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Drugs for Non-Small Cell Lung Cancer Revenue, by Type (Million USD) (2018-2028)
Table 4. Drugs for Non-Small Cell Lung Cancer Production, by Type (K Unit) (2018-2028)
Table 5. Drugs for Non-Small Cell Lung Cancer Demand (K Unit) by Application (2018-2028)
Table 6. Drugs for Non-Small Cell Lung Cancer Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Drugs for Non-Small Cell Lung Cancer Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Drugs for Non-Small Cell Lung Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Drugs for Non-Small Cell Lung Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Drugs for Non-Small Cell Lung Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Drugs for Non-Small Cell Lung Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Drugs for Non-Small Cell Lung Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Drugs for Non-Small Cell Lung Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Drugs for Non-Small Cell Lung Cancer Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Drugs for Non-Small Cell Lung Cancer in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Bristol-Myers Squibb Profiles
Table 61. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 62. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Bristol-Myers Squibb Strategic initiatives
Table 64. GlaxoSmithKline Profiles
Table 65. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 66. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. GlaxoSmithKline Strategic initiatives
Table 68. Menarini Profiles
Table 69. Menarini Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 70. Menarini Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Menarini Strategic initiatives
Table 72. Sanofi Profiles
Table 73. Sanofi Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 74. Sanofi Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Sanofi Strategic initiatives
Table 76. Ziopharm Oncology Profiles
Table 77. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 78. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Ziopharm Oncology Strategic initiatives
Table 80. Alchemia Profiles
Table 81. Alchemia Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 82. Alchemia Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Alchemia Strategic initiatives
Table 84. Amgen Profiles
Table 85. Amgen Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 86. Amgen Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Amgen Strategic initiatives
Table 88. Apotex Profiles
Table 89. Apotex Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 90. Apotex Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Apotex Strategic initiatives
Table 92. BioMarin Pharmaceutical Profiles
Table 93. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 94. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. BioMarin Pharmaceutical Strategic initiatives
Table 97. CellAct Pharma Profiles
Table 98. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 99. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. CellAct Pharma Strategic initiatives
Table 101. Cerulean Pharma Profiles
Table 102. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 103. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Cerulean Pharma Strategic initiatives
Table 105. Cipla Profiles
Table 106. Cipla Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 107. Cipla Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Cipla Strategic initiatives
Table 109. Cornerstone Pharmaceuticals Profiles
Table 110. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 111. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Cornerstone Pharmaceuticals Strategic initiatives
Table 113. Curis Profiles
Table 114. Curis Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 115. Curis Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Curis Strategic initiatives
Table 117. CytRx Profiles
Table 118. CytRx Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 119. CytRx Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 120. CytRx Strategic initiatives
Table 121. Eli Lilly Profiles
Table 122. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 123. Eli Lilly Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 124. Eli Lilly Strategic initiatives
Table 125. Exelixis Profiles
Table 126. Exelixis Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 127. Exelixis Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 128. Exelixis Strategic initiatives
Table 129. Fresenius Kabi Profiles
Table 130. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 131. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 132. Fresenius Kabi Strategic initiatives
Table 133. Genentech Profiles
Table 134. Genentech Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 135. Genentech Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 136. Genentech Strategic initiatives
Table 137. Hikma Pharmaceuticals Profiles
Table 138. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 139. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 140. Hikma Pharmaceuticals Strategic initiatives
Table 141. Hospira Profiles
Table 142. Hospira Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 143. Hospira Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 144. Hospira Strategic initiatives
Table 145. Intas Pharmaceuticals Profiles
Table 146. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 147. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 148. Intas Pharmaceuticals Strategic initiatives
Table 149. Karyopharm Therapeutics Profiles
Table 150. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 151. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 152. Karyopharm Therapeutics Strategic initiatives
Table 153. Kyowa Hakko Kirin Profiles
Table 154. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 155. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 156. Kyowa Hakko Kirin Strategic initiatives
Table 157. Ligand Pharmaceuticals Profiles
Table 158. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Introduction
Table 159. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (Unit), Revenue (Million USD) (2018-2022)
Table 160. Ligand Pharmaceuticals Strategic initiatives
